Our group aims to develop new T-cell based concepts for cancer immunotherapy that overcome the major challenge of self-tolerance in cancer. To this end, one of our main strategies involves studies of how the immune system from healthy donors can target patient cancer cells. We have a strong focus on the development of new technologies that allow high-throughput identification of therapeutic targets that can evoke immune responses, as lack of immunogenic targets represents a major limitation in therapeutic efficacy. The group furthermore has a strong translational focus and performs penetrating mechanistic analyses in clinical trials together with our clinical partners.
Johanna Olweus was awarded an ERC Consolidator Grant (September 2020-2025) to pursue the goal of utilizing the mechanism of transplant rejection to identify self-reactive, therapeutic TCRs from healthy donors with the project “OUTSOURCE”. In Dec 2021 the group published proof-of-concept for this approach in Nature Biotechnology.
Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma
Clin Cancer Res, 28 (10), 2160-2166
Chasing neoantigens; invite naïve T cells to the party
Curr Opin Immunol, 75, 102172
Tryptophan depletion results in tryptophan-to-phenylalanine substitutants
Nature, 603 (7902), 721-727